Evaluation of the therapeutic regimen in COVID-19 in transplant patients: where do immunomodulatory and antivirals stand?

Mojtaba ShafiekhaniFarbod ShahabinezhadTahmoores NiknamSeyed Ahmad TaraElham HaemParviz MardaniZahra ZareSedigheh JafarianKhatereh Mirzad JahromiSara ArabsheybaniYalda Sadat MoeiniJalile AlaviSeyed Soroush JalaliMaryam SalimiReza ShahriariradSeyed Ali Malekhosseini

Published in: Virology journal (2021)

The administration of Remdesivir as an anti-viral and Tocilizumab as an immunomodulatory drug in solid-organ transplant recipients could be promising treatments of choice to manage COVID-19.

Keyphrases

sars cov
coronavirus disease
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
rheumatoid arthritis
peritoneal dialysis
prognostic factors
emergency department
respiratory syndrome coronavirus
patient reported outcomes
juvenile idiopathic arthritis
patient reported
drug induced